Patents by Inventor Sharon R. Nahill

Sharon R. Nahill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulators of TNF-? signaling
    Patent number: 9579325
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: February 28, 2017
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Frederic Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators Of TNF-Alpha Signaling
    Publication number: 20150126512
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Application
    Filed: November 25, 2014
    Publication date: May 7, 2015
    Applicant: GENZYME CORPORATION
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Frederic Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-? signaling
    Patent number: 8921547
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: December 30, 2014
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Frederic Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-Alpha Signaling
    Publication number: 20130310388
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Application
    Filed: July 19, 2013
    Publication date: November 21, 2013
    Applicant: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, JR., Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-?signaling
    Patent number: 8518999
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: December 1, 2005
    Date of Patent: August 27, 2013
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Anti-inflammatory compositions and methods
    Patent number: 7186725
    Abstract: The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus. The compositions comprise disubstituted ureas of Formulas I, II, III or IV: R1—NH—CO—NH-Q-R2Formula I: Et-NH—CO—NH-Q-R2:??Formula (II) Et-NH—CO—NH—(CH2)3—NR6R7:??Formula (III) Me2N—(CH2)3—NH—CO—NH-Q-R2.
    Type: Grant
    Filed: December 23, 2003
    Date of Patent: March 6, 2007
    Assignee: Genzyme Corporation
    Inventors: Mark M. Staveski, Robert J. Miller, Sharon R. Nahill
  • Modulators of TNF-? signaling
    Patent number: 7034031
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: April 25, 2006
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-? signaling
    Patent number: 6969728
    Abstract: The present invention provides compounds which are modulators of TNF-? signaling and methods of use thereof for treating a patient having a TNF-? mediated condition.
    Type: Grant
    Filed: May 10, 2001
    Date of Patent: November 29, 2005
    Assignee: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Anti-inflammatory compositions and methods
    Publication number: 20040180871
    Abstract: The present invention provides compositions and their use in the treatment of inflammatory diseases caused by T-cell proliferation such as sepsis, inflammatory bowel diseases, autoimmune encephalomyelitis, or lupus.
    Type: Application
    Filed: December 23, 2003
    Publication date: September 16, 2004
    Applicant: Genzyme Corporation
    Inventors: Mark M. Staveski, Robert J. Miller, Sharon R. Nahill
  • Modulators of TNF-alfa signaling
    Publication number: 20040171617
    Abstract: The present invention provides compounds which are modulators of TNF-&agr; signaling and methods of use thereof for treating a patient having a TNF-&agr; mediated condition.
    Type: Application
    Filed: March 10, 2004
    Publication date: September 2, 2004
    Applicant: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill, John M. Williams, Hans-Peter Biemann
  • Modulators of TNF-alpha signaling
    Publication number: 20020119988
    Abstract: The present invention provides compounds which are modulators of TNF-&agr; signaling and methods of use thereof for treating a patient having a TNF-&agr; mediated condition.
    Type: Application
    Filed: May 10, 2001
    Publication date: August 29, 2002
    Applicant: Genzyme Corporation
    Inventors: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred Vinick, Shuang Qiao, Sharon R. Nahill